| SHTDY Stock | | | USD 13.31 0.33 2.54% |
President
Mr. Liu Yong serves as President, Executive Director of the Company. Mr. Liu joined the Group in January 2003, he has served as the Groups president since November 2017 and executive director since December 2017. Mr. Liu has over 26 years of working experience, over 23 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelors degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a masters degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Corporation and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. from April 2003 to November 2009. He served as vice president of the Company from January 2009 to November 2017, secretary to the Board of the Company from October 2016 to November 2017, and has served as chief legal advisor of the Company from January 2014 to December 2017. Mr. Liu is currently the director of Sinopharm Industrial Investment Co., Ltd. and Sinopharm Holding Guoda Drugstores Co., Ltd., and chairman of Sinopharm Lerentang Pharmaceutical Co., Ltd. and China National Accord Medicines Co., Ltd. since 2017.
| Age | 54 |
| Tenure | 7 years |
| Phone | 86 21 2305 2666 |
| Web | https://www.sinopharmgroup.com.cn |
SINOPHARM GROUP Management Efficiency
The company has return on total asset
(ROA) of
0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. SINOPHARM GROUP's management efficiency ratios could be used to measure how well SINOPHARM GROUP manages its routine affairs as well as how well it operates its assets and liabilities.
SINOPHARM GROUP LTD has accumulated 8.42
B in total debt with debt to equity ratio
(D/E) of 0.72, which is about average as compared to similar companies. SINOPHARM GROUP LTD has a current ratio of 1.28, suggesting that it
may have difficulties to pay its financial obligations in time and when they become due. Debt can assist SINOPHARM GROUP until it has trouble settling it off, either with new capital or with free cash flow. So, SINOPHARM GROUP's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SINOPHARM GROUP LTD sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SINOPHARM to invest in growth at high rates of return. When we think about SINOPHARM GROUP's use of debt, we should always consider it together with cash and equity.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd. Sinopharm is traded on OTC Exchange in the United States. SINOPHARM GROUP LTD [SHTDY] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
SINOPHARM GROUP LTD Leadership Team
Elected by the shareholders, the SINOPHARM GROUP's board of directors comprises two types of representatives: SINOPHARM GROUP inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SINOPHARM. The board's role is to monitor SINOPHARM GROUP's management team and ensure that shareholders' interests are well served. SINOPHARM GROUP's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SINOPHARM GROUP's outside directors are responsible for providing unbiased perspectives on the board's policies.
SINOPHARM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is SINOPHARM GROUP a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for SINOPHARM Pink Sheet Analysis
When running SINOPHARM GROUP's price analysis, check to
measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to
predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.